Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.38 - $1.05 $4,130 - $11,413
-10,870 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$0.52 - $1.3 $5,652 - $14,131
10,870 New
10,870 $7,000
Q3 2021

Nov 15, 2021

SELL
$1.15 - $1.62 $53,355 - $75,161
-46,396 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$1.31 - $2.14 $43,704 - $71,394
-33,362 Reduced 41.83%
46,396 $74,000
Q1 2021

May 17, 2021

BUY
$1.85 - $3.04 $85,405 - $140,341
46,165 Added 137.42%
79,758 $157,000
Q4 2020

Feb 16, 2021

BUY
$1.58 - $2.37 $53,076 - $79,615
33,593 New
33,593 $80,000
Q2 2019

Aug 14, 2019

SELL
$4.76 - $8.1 $75,869 - $129,105
-15,939 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$5.15 - $8.53 $82,085 - $135,959
15,939 New
15,939 $0

Others Institutions Holding HOTH

About Hoth Therapeutics, Inc.


  • Ticker HOTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 1,288,470
  • Market Cap $1.11M
  • Description
  • Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor ...
More about HOTH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.